Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609847 | 0.89 | AHR (0.48) | CYP1A2CYP2A6AHRGAAALDH1A1 | |
| SCHEMBL15845332 | 0.89 | — | — | |
| SCHEMBL1611847 | 0.89 | AHR (0.48) | CYP1A2CYP2A6AHRGAAALDH1A1 | |
| SCHEMBL13203015 | 0.82 | AHR (0.54) | CYP2A6AHRGAAALDH1A1TDP1 | |
| SCHEMBL9874879 | 0.78 | MAOB (0.40) | GAAALDH1A1MMP12 | |
| SCHEMBL25137402 | 0.77 | MAPT (0.38) | CYP1A2CYP2A6AHRGAAALDH1A1 | |
| SCHEMBL18622818 | 0.77 | CYP2A6 (0.54) | CYP1A2CYP2A6AHRGAAALDH1A1 | |
| SCHEMBL16426127 | 0.77 | AHR (0.74) | AHRALDH1A1MAPT | |
| SCHEMBL13255905 | 0.77 | AHR (0.38) | CYP1A2CYP2A6AHRGAAALDH1A1 | |
| SCHEMBL16426097 | 0.77 | AHR (0.74) | AHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639327-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display device using the same | DIC CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20230131540-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT AND COMPOUND | DIC CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639327-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display device using the same | SKP1, PKN1, KTN1 | CYP1A2 3295/4885CYP2A6 4156/4885AHR 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.